文献速递中医妇科中药与中成药合理使用

妇科千金胶囊治疗巴基斯坦盆腔炎患者的随机双盲阳性对照II期临床试验

A randomized, double-blind, positive-controlled, Phase-II clinical trial to evaluate efficacy and safety of Fuke Qianjin capsule in Pakistani patients with pelvic inflammatory disease.
PubMed 文献 · Front Pharmacol · 2024-03-22

该II期随机双盲阳性对照试验在巴基斯坦单中心纳入198例轻中度症状盆腔炎患者,比较妇科千金胶囊联合甲硝唑与多西环素联合甲硝唑的疗效与安全性。意向性分析显示试验组主要疗效84.9%优于对照组71.6%(p=0.0370),次要疗效及局部体征改善无显著差异,试验药对多西环素非劣效,不良事件发生率4.7%且无严重不良事件。

要点

  • 妇科千金胶囊联合甲硝唑治疗轻中度盆腔炎的主要疗效优于多西环素联合甲硝唑。
  • 试验药在次要疗效、白带及宫颈分泌物改善方面对多西环素非劣效。
  • 不良事件发生率4.7%,两组间无统计学差异,无严重不良事件。

核心结论

  • 妇科千金胶囊在治疗轻中度盆腔炎患者中對多西环素非劣效,疗效、安全性和耐受性相当。

研究设计与样本

  • II期随机双盲阳性对照临床试验,2021年9月21日至2022年3月11日在巴基斯坦单中心进行。
  • 共纳入198例轻中度症状盆腔炎女性患者,按1:1随机分为试验组(n=99)和对照组(n=99)。
  • 试验组接受甲硝唑片2片+多西环素模拟剂1片,每日两次,共14天;妇科千金胶囊2粒,每日三次,饭后服,共28天。
  • 对照组接受甲硝唑片2片+多西环素片1片,每日两次,共14天;妇科千金胶囊模拟剂2粒,每日三次,饭后服,共28天。

主要发现

  • 意向性分析主要疗效(盆腔疼痛VAS改善)试验组84.9%,对照组71.6%,差异有统计学意义(p=0.0370;95%CI -0.2568至-0.0088)。
  • 次要临床疗效试验组88.4%,对照组82.7%,无显著差异(p=0.2977;95%CI -0.1632至0.0501)。
  • 局部体征改善试验组95.8%,对照组76.9%,无显著差异(p=0.0542;95%CI -0.3697至-0.0085)。
  • 组间非劣效比较显示95%CI上限小于0.15,满足试验组对对照组的非劣效要求。
  • 白带及宫颈分泌物临床体征改善率两组无差异,表明妇科千金胶囊对多西环素非劣效。

临床怎么用

  • 对于轻中度症状盆腔炎患者,可考虑使用妇科千金胶囊联合甲硝唑作为治疗选择。
  • 妇科千金胶囊在盆腔疼痛改善方面可能优于多西环素联合甲硝唑方案。
  • 使用期间需监测不良事件,该试验中不良事件发生率低且无严重事件。

局限性

  • 单中心研究,样本量198例,结论外推需谨慎。
  • 研究人群为巴基斯坦患者,其他人群的适用性需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ethnopharmacological relevance: Pelvic inflammatory disease (PID) is a frequently occurring gynecological disorder mainly caused by the inflammation of a woman's upper genital tract. Generally, antibiotics are used for treating PID, but prolonged use poses potential risks of gut bacterial imbalance, bacterial resistance, super bacteria production, and associated adverse reactions. Traditional Chinese medicine (TCM) has shown unique advantages in various ailments and has received widespread clinical research attention. Fuke Qianjin (FUKE) capsule is an approved National Medical Products Administration (NMPA License No. Z20020024) Chinese herbal prescription that has been widely used individually or in combination with other Western medicines for the treatment of various gynecological inflammatory diseases, including chronic cervicitis, endometritis, and chronic PID. Aim: This clinical trial was designed to assess the safety and efficacy of FUKE capsule in mild-to-moderate symptomatic PID patients. Materials and methods: This phase 2, randomized, double-blind, positive controlled clinical trial was conducted in mild-to-moderate symptomatic PID patients at a single center in Pakistan from 21 September 2021 to 11 March 2022. Eligible female participants were randomly assigned to a test and a control group with a ratio of 1:1. The test group subjects received two metronidazole (METRO) tablets and one doxycycline hyclate (DOXY) simulant at a time, twice daily for 14 days, and two Fuke Qianjin (FUKE) capsules, three times a day after a meal for 28 days. Subjects in the control group received two METRO tablets and one DOXY tablet at a time, twice daily for 14 days, and two FUKE simulant capsules, three times a day after meal for 28 days. The primary efficacy outcome was an improvement in pelvic pain symptoms assessed through a visual analog scale (VAS). The secondary outcomes were the improvement in secondary efficacy symptoms like local physical signs, clinical assessment of leucorrhea and cervical secretions through laboratory examination, and improvement in the maximum area of pelvic effusion assessed through gynecological ultrasound after the treatment. The safety outcomes were assessed through vital signs, laboratory tests, electrocardiogram findings, and adverse events/serious adverse events. Results: A total of 198 subjects with active PID were randomly assigned to a test group (n = 99) and a control group (n = 99). The baseline characteristics of the subjects in the two groups were similar. In the intention-to-treat analysis, the primary efficacy was 84.9% for the test group and 71.6% for the control group, with a statistically significant difference (p = 0.0370; 95% CI -0.2568 to -0.0088). The secondary clinical efficacy was 88.4% for the test group and 82.7% for the control group, with no significant difference (p = 0.2977; 95% CI -0.1632 to 0.0501). The improvement in local physical signs was 95.8% for the test group and 76.9% for the control group, with no significant difference (p = 0.0542; 95% CI -0.3697 to -0.0085). The inter-group non-inferiority comparison showed that the upper limit of the 95% CI was less than 0.15 and thus met the non-inferiority requirements of the test group to the control group. The results of clinical signs of leucorrhea and cervical secretions showed that there was no difference in the rate of improvement between the test and control groups, indicating that FUKE was non-inferior to DOXY. A total of 14 adverse events in eight subjects were observed in the trial, with an incidence rate of 4.7%. Four subjects in each group experienced seven adverse events with 4.5% and 4.8% incidence rates of adverse reactions in the test and control groups, with no statistically significant differences (p = 0.2001). No serious adverse events occurred in the trial. Conclusion: The results of this trial indicate that the test drug (Fuke Qianjin capsule) is non-inferior to the control drug (doxycycline hyclate tablet) in treating mild-to-moderate PID patients with comparable efficacy, safety, and tolerability to the control drug. Clinical Trial Registration: www.clinicaltrials.gov, identifier NCT04723069.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Shah MR, Khan SN, Fatima S, et al. A randomized, double-blind, positive-controlled, Phase-II clinical trial to evaluate efficacy and safety of Fuke Qianjin capsule in Pakistani patients with pelvic inflammatory disease. Front Pharmacol. 2024. PMID: 38584600. doi:10.3389/fphar.2024.1287321

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。